Acute Myeloid Leukemia Treatment Market Size, Share & Trends Analysis Report By Disease (Myeloblastic Leukemia, Myelomonocytic Leukemia), By Treatment (Chemotherapy), By Route Of Administration, By End-use, By Region, And Segment Forecasts, 2024 - 2030
Market Size & Trends
The global acute myeloid leukemia treatment market size was estimated at USD 3.18 billion in 2023 and is expected to grow at a CAGR of 10.44% from 2024 to 2030. The increasing need for advanced therapeutics is also a high-impact rendering driver of this market. Rising incidences of acute myeloid leukemia therapeutics are attributed to factors such as genetic mutations, unhealthy lifestyles, continued exposure to hazardous chemicals such as benzene, and radiation exposure. Moreover, the increasing geriatric population base and growing unmet healthcare needs are expected to boost the market growth further. According to the estimates given by American Cancer Society in 2024, around 20,800 people were diagnosed with Acute Myeloid Leukemia.
The market for Acute Myeloid Leukemia (AML) treatment is driven by several key factors related to therapeutics and treatments. One significant driver is the continuous advancement and approval of novel therapies. For instance, in July 2023, the FDA approved quizartinib (Vanflyta) in combination with standard chemotherapies for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML. This approval highlights the importance of targeted therapies that address specific genetic mutations in AML, improving patient outcomes and expanding treatment options. Such advancements not only enhance the efficacy of treatment regimens but also provide new hope for patients with limited options under conventional therapies.
Another major driver is the significant investment in research and development by pharmaceutical companies. For instance, a USD 6 million grant awarded in December 2023 for developing novel therapies targeting high-risk AML patients reflects the strong commitment to innovation in the field. This investment is crucial for discovering new treatment modalities and improving existing ones, thus driving market growth. Additionally, collaborations and partnerships among pharmaceutical companies, research institutions, and academic centers are pivotal in accelerating the development of new AML therapies, further stimulating market expansion.
Despite these advancements, the AML treatment market faces several restraints. One of the primary challenges is the high cost associated with new therapies. The development, approval, and commercialization of innovative treatments often come with substantial expenses, making them expensive for patients and healthcare systems. This financial burden can limit access to the latest treatments, especially in low- and middle-income countries, thereby hindering the overall market growth.
Another significant restraint is the adverse side effects associated with AML treatments. While chemotherapy remains a cornerstone of AML treatment, it can cause severe side effects such as fatigue, nausea, and increased risk of infections. These side effects can significantly impact the quality of life for patients and sometimes lead to treatment discontinuation. Even newer targeted therapies, despite their precision, can pose challenges to patient tolerance. For instance, the combination of venetoclax with other treatments, while promising, has shown side effects that necessitate careful management.
Furthermore, the stringent regulatory environment poses another challenge. The approval process for new drugs is rigorous, requiring extensive clinical trials to ensure safety and efficacy. While these regulations are essential for patient safety, they can delay the introduction of new therapies to the market. This prolonged approval process can be a barrier to the timely availability of innovative treatments, impacting the market's ability to respond quickly to emerging therapeutic needs.
Global Acute Myeloid Leukemia Treatment Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research segmented the global acute myeloid leukemia treatment market report based on disease, treatment, route of administration, end-use, and region.
- Disease Outlook (Revenue, USD Million, 2018 - 2030)
- Myeloblastic Leukemia
- Myelomonocytic Leukemia
- Promyelocytic Leukemia
- Monocytic Leukemia
- Other Diseases
- Treatment Outlook (Revenue, USD Million, 2018 - 2030)
- Chemotherapy
- Anti-metabolites
- Alkylating Agents
- Anthracycline Drugs
- Others
- Targeted Therapy
- FLT3 Inhibitors
- Rydapt
- Vanflyta
- Xospata
- IDH Inhibitors
- Tibsovo
- Rezlidhia
- Idhifa
- Mylotarg
- BCL-2 Inhibitor
- Venclexta
- Hedgehog Pathway Inhibitor
- Daurismo
- Immunotherapy
- Bispecific Antibodies
- Antibody-drug Conjugates
- Immune Checkpoint Inhibitors
- Chimeric Antigen Receptor (CAR) T-cell Therapy
- Other Treatments
- Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
- Parenteral
- Oral
- End Use Outlook (Revenue, USD Million, 2018 - 2030)
- Hospital and Clinics
- Specialty Centers
- Homecare Settings
- Ambulatory Care Centers
- Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Disease
- 1.2.2. Treatment
- 1.2.3. Route of Administration
- 1.2.4. End Use
- 1.2.5. Regional scope
- 1.2.6. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Disease outlook
- 2.2.2. Treatment outlook
- 2.2.3. Route of Administration outlook
- 2.2.4. End Use outlook
- 2.2.5. Regional outlook
- 2.3. Competitive Insights
- Chapter 3. Acute Myeloid Leukemia Treatment Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Increasing prevalence of acute myeloid leukemia
- 3.2.1.2. Advancements in diagnostic techniques
- 3.2.1.3. Growing investments in R&D techniques
- 3.2.2. Market restraint analysis
- 3.2.2.1. High cost of treatment
- 3.2.2.2. Limited treatment options
- 3.3. Acute Myeloid Leukemia Treatment Market Analysis Tools
- 3.3.1. Industry Analysis – Porter’s Five Forces
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.3.3. Pipeline Analysis
- Chapter 4. Acute Myeloid Leukemia Treatment Market: Disease Estimates & Trend Analysis
- 4.1. Global Acute Myeloid Leukemia Treatment Market: Disease Dashboard
- 4.2. Global Acute Myeloid Leukemia Treatment Market: Disease Movement Analysis
- 4.3. Global Acute Myeloid Leukemia Treatment Market by Disease, Revenue
- 4.4. Myeloblastic Leukemia
- 4.4.1. Myeloblastic leukemia market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5. Myelomonocytic Leukemia
- 4.5.1. Myelomonocytic leukemia market estimates and forecasts 2018 to 2030 (USD Million)
- 4.6. Promyelocytic Leukemia
- 4.6.1. Promyelocytic leukemia market estimates and forecasts 2018 to 2030 (USD Million)
- 4.7. Monocytic Leukemia
- 4.7.1. Monocytic leukemia market estimates and forecasts 2018 to 2030 (USD Million)
- 4.8. Other Diseases
- 4.8.1. Other diseases market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 5. Acute Myeloid Leukemia Treatment Market: Treatment Estimates & Trend Analysis
- 5.1. Global Acute Myeloid Leukemia Treatment Market: Treatment Dashboard
- 5.2. Global Acute Myeloid Leukemia Treatment Market: Treatment Movement Analysis
- 5.3. Global Acute Myeloid Leukemia Treatment Market Estimates and Forecasts, By Treatment, Revenue (USD Million)
- 5.4. Chemotherapy
- 5.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.2. Anti-metabolites
- 5.4.2.1. Anti-metabolites market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.3. Alkylating agents
- 5.4.3.1. Alkylating agents market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.4. Anthracycline drugs
- 5.4.4.1. Anthracycline drugs market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.5. Others
- 5.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5. Targeted Therapy
- 5.5.1. Targeted therapy market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5.2. FLT3 inhibitors
- 5.5.2.1. FLT3 inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5.2.1.1. Rydapt
- 5.5.2.1.1.1. Rydapt market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5.2.1.2. Vanflyta
- 5.5.2.1.2.1. Vanflyta market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5.2.1.3. Xospata
- 5.5.2.1.3.1. Xospata market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5.3. IDH inhibitors
- 5.5.3.1. IDH inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5.3.1.1. Tibsovo
- 5.5.3.1.1.1. Tibsovo market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5.3.1.2. Rezlidhia
- 5.5.3.1.2.1. Rezlidhia market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5.3.1.3. Idhifa
- 5.5.3.1.3.1. Idhifa market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5.4. Mylotarg
- 5.5.4.1. Mylotarg market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5.5. BCL-2 inhibitor
- 5.5.5.1. BCL-2 inhibitor market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5.5.1.1. Venclexta
- 5.5.5.1.1.1. Venclexta market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5.6. Hedgehog pathway inhibitor
- 5.5.6.1. Hedgehog pathway inhibitor market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5.6.1.1. Daurismo
- 5.5.6.1.1.1. Daurismo market estimates and forecasts 2018 to 2030 (USD Million)
- 5.6. Immunotherapy
- 5.6.1. Immunotherapy market estimates and forecasts 2018 to 2030 (USD Million)
- 5.6.1.1. Bispecific antibodies
- 5.6.1.1.1. Bispecific antibodies market estimates and forecasts 2018 to 2030 (USD Million)
- 5.6.1.2. Antibody-drug conjugates
- 5.6.1.3. Antibody-drug conjugates market estimates and forecasts 2018 to 2030 (USD Million)
- 5.6.1.4. Immune checkpoint inhibitors
- 5.6.1.4.1. Immune checkpoint inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
- 5.6.1.5. Chimeric antigen receptor (CAR) T-cell therapy
- 5.6.1.5.1. Chimeric antigen receptor (CAR) T-cell therapy market estimates and forecasts 2018 to 2030 (USD Million)
- 5.7. Other Treatments
- 5.7.1. Other treatments market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 6. Acute Myeloid Leukemia Treatment Market: Route of Administration Estimates & Trend Analysis
- 6.1. Global Acute Myeloid Leukemia Treatment Market: Route of Administration Dashboard
- 6.2. Global Acute Myeloid Leukemia Treatment Market: Route of Administration Movement Analysis
- 6.3. Global Acute Myeloid Leukemia Treatment Market Estimates and Forecasts, by Route of Administration, Revenue (USD Million)
- 6.4. Parenteral
- 6.4.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5. Oral
- 6.5.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 7. Acute Myeloid Leukemia Treatment Market: End Use Estimates & Trend Analysis
- 7.1. Global Acute Myeloid Leukemia Treatment Market: End Use Dashboard
- 7.2. Global Acute Myeloid Leukemia Treatment Market: End Use Movement Analysis
- 7.3. Global Acute Myeloid Leukemia Treatment Market Estimates and Forecasts by End Use, Revenue (USD Million)
- 7.4. Hospital and Clinics
- 7.4.1. Hospital and clinics market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5. Specialty Centers
- 7.5.1. Specialty Centers market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6. Homecare Setting
- 7.6.1. Homecare setting market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 8. Acute Myeloid Leukemia Treatment Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, and Route of Administration
- 8.1. Regional Dashboard
- 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 8.3. North America
- 8.3.1. U.S.
- 8.3.1.1. Key country dynamics
- 8.3.1.2. Regulatory framework/ reimbursement structure
- 8.3.1.3. Competitive scenario
- 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 8.3.2. Canada
- 8.3.2.1. Key country dynamics
- 8.3.2.2. Regulatory framework/ reimbursement structure
- 8.3.2.3. Competitive scenario
- 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 8.3.3. Mexico
- 8.3.3.1. Key country dynamics
- 8.3.3.2. Regulatory framework/ reimbursement structure
- 8.3.3.3. Competitive scenario
- 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4. Europe
- 8.4.1. UK
- 8.4.1.1. Key country dynamics
- 8.4.1.2. Regulatory framework/ reimbursement structure
- 8.4.1.3. Competitive scenario
- 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.2. Germany
- 8.4.2.1. Key country dynamics
- 8.4.2.2. Regulatory framework/ reimbursement structure
- 8.4.2.3. Competitive scenario
- 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.3. France
- 8.4.3.1. Key country dynamics
- 8.4.3.2. Regulatory framework/ reimbursement structure
- 8.4.3.3. Competitive scenario
- 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.4. Italy
- 8.4.4.1. Key country dynamics
- 8.4.4.2. Regulatory framework/ reimbursement structure
- 8.4.4.3. Competitive scenario
- 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.5. Spain
- 8.4.5.1. Key country dynamics
- 8.4.5.2. Regulatory framework/ reimbursement structure
- 8.4.5.3. Competitive scenario
- 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.6. Norway
- 8.4.6.1. Key country dynamics
- 8.4.6.2. Regulatory framework/ reimbursement structure
- 8.4.6.3. Competitive scenario
- 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.7. Sweden
- 8.4.7.1. Key country dynamics
- 8.4.7.2. Regulatory framework/ reimbursement structure
- 8.4.7.3. Competitive scenario
- 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 8.4.8. Denmark
- 8.4.8.1. Key country dynamics
- 8.4.8.2. Regulatory framework/ reimbursement structure
- 8.4.8.3. Competitive scenario
- 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5. Asia Pacific
- 8.5.1. Japan
- 8.5.1.1. Key country dynamics
- 8.5.1.2. Regulatory framework/ reimbursement structure
- 8.5.1.3. Competitive scenario
- 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.2. China
- 8.5.2.1. Key country dynamics
- 8.5.2.2. Regulatory framework/ reimbursement structure
- 8.5.2.3. Competitive scenario
- 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.3. India
- 8.5.3.1. Key country dynamics
- 8.5.3.2. Regulatory framework/ reimbursement structure
- 8.5.3.3. Competitive scenario
- 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.4. Australia
- 8.5.4.1. Key country dynamics
- 8.5.4.2. Regulatory framework/ reimbursement structure
- 8.5.4.3. Competitive scenario
- 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.5. South Korea
- 8.5.5.1. Key country dynamics
- 8.5.5.2. Regulatory framework/ reimbursement structure
- 8.5.5.3. Competitive scenario
- 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.6. Thailand
- 8.5.6.1. Key country dynamics
- 8.5.6.2. Regulatory framework/ reimbursement structure
- 8.5.6.3. Competitive scenario
- 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6. Latin America
- 8.6.1. Brazil
- 8.6.1.1. Key country dynamics
- 8.6.1.2. Regulatory framework/ reimbursement structure
- 8.6.1.3. Competitive scenario
- 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.2. Argentina
- 8.6.2.1. Key country dynamics
- 8.6.2.2. Regulatory framework/ reimbursement structure
- 8.6.2.3. Competitive scenario
- 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7. MEA
- 8.7.1. South Africa
- 8.7.1.1. Key country dynamics
- 8.7.1.2. Regulatory framework/ reimbursement structure
- 8.7.1.3. Competitive scenario
- 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.2. Saudi Arabia
- 8.7.2.1. Key country dynamics
- 8.7.2.2. Regulatory framework/ reimbursement structure
- 8.7.2.3. Competitive scenario
- 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.3. UAE
- 8.7.3.1. Key country dynamics
- 8.7.3.2. Regulatory framework/ reimbursement structure
- 8.7.3.3. Competitive scenario
- 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.4. Kuwait
- 8.7.4.1. Key country dynamics
- 8.7.4.2. Regulatory framework/ reimbursement structure
- 8.7.4.3. Competitive scenario
- 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 9. Competitive Landscape
- 9.1. Company/Competition Categorization
- 9.2. Vendor Landscape
- 9.2.1. List of key distributors and channel partners
- 9.2.2. Key customers
- 9.2.3. Key company market share analysis, 2023
- 9.2.4. Astellas Pharma Inc.
- 9.2.4.1. Company overview
- 9.2.4.2. Financial performance
- 9.2.4.3. Product benchmarking
- 9.2.4.4. Strategic initiatives
- 9.2.5. Bristol Myers Squibb Company
- 9.2.5.1. Company overview
- 9.2.5.2. Financial performance
- 9.2.5.3. Product benchmarking
- 9.2.5.4. Strategic initiatives
- 9.2.6. Celgene Corporation
- 9.2.6.1. Company overview
- 9.2.6.2. Financial performance
- 9.2.6.3. Product benchmarking
- 9.2.6.4. Strategic initiatives
- 9.2.7. Daiichi Sankyo Company, Limited
- 9.2.7.1. Company overview
- 9.2.7.2. Financial performance
- 9.2.7.3. Product benchmarking
- 9.2.7.4. Strategic initiatives
- 9.2.8. Jazz Pharmaceuticals, plc
- 9.2.8.1. Company overview
- 9.2.8.2. Financial performance
- 9.2.8.3. Product benchmarking
- 9.2.8.4. Strategic initiatives
- 9.2.9. Novartis AG
- 9.2.9.1. Company overview
- 9.2.9.2. Financial performance
- 9.2.9.3. Product benchmarking
- 9.2.9.4. Strategic initiatives
- 9.2.10. Otsuka Pharmaceuticals Co., Ltd.
- 9.2.10.1. Company overview
- 9.2.10.2. Financial performance
- 9.2.10.3. Product benchmarking
- 9.2.10.4. Strategic initiatives
- 9.2.11. Pfizer, Inc.
- 9.2.11.1. Company overview
- 9.2.11.2. Financial performance
- 9.2.11.3. Product benchmarking
- 9.2.11.4. Strategic initiatives
- 9.2.12. Rigel Pharmaceuticals, Inc.
- 9.2.12.1. Company overview
- 9.2.12.2. Financial performance
- 9.2.12.3. Product benchmarking
- 9.2.12.4. Strategic initiatives
- 9.2.13. Merck & Co., Inc.
- 9.2.13.1. Company overview
- 9.2.13.2. Financial performance
- 9.2.13.3. Product benchmarking
- 9.2.13.4. Strategic initiatives
- 9.2.14. Sanofi
- 9.2.14.1. Company overview
- 9.2.14.2. Financial performance
- 9.2.14.3. Product
- 9.2.14.4. Benchmarking
- 9.2.14.5. Strategic initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook